Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker GCBC
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 9, 2026 | Michelle M. Plummer Director | GCBC Greene Bancorp, Inc. | Sale | 10,000 | $35.52 | $355.2K Sale | Form 4 ↗ |
| Jun 11, 2026 | Michelle M. Plummer Director | GCBC Greene Bancorp, Inc. | Sale | 10,000 | $28.77 | $287.7K Sale | Form 4 ↗ |
| Apr 28, 2026 | John Brust Director | GCBC Greene Bancorp, Inc. | Buy | 2,041 | $24.50 | $50.0K Buy | Form 4 ↗ |
| Apr 27, 2026 | John Brust Director | GCBC Greene Bancorp, Inc. | Buy | 1,040 | $24.06 | $25.0K Buy | Form 4 ↗ |
| Apr 27, 2026 | John Brust Director | GCBC Greene Bancorp, Inc. | Buy | 1,040 | $24.05 | $25.0K Buy | Form 4 ↗ |
| Mar 18, 2026 | Peter W. Hogan Director | GCBC Greene Bancorp, Inc. | Buy | 3,000 | $22.10 | $66.3K Buy | Form 4 ↗ |
| Mar 18, 2026 | Tejraj S. Hada Director | GCBC Greene Bancorp, Inc. | Buy | 4,000 | $21.95 | $87.8K Buy | Form 4 ↗ |
| Mar 17, 2026 | Tejraj S. Hada Director | GCBC Greene Bancorp, Inc. | Buy | 2,000 | $21.99 | $44.0K Buy | Form 4 ↗ |
| Mar 5, 2026 | Nick Barzee SVP and CFO | GCBC Greene Bancorp, Inc. | Buy | 1,280 | $22.55 | $28.9K Buy | Form 4 ↗ |
| Mar 2, 2026 | Christopher Cannucciari Director | GCBC Greene Bancorp, Inc. | Buy | 1,300 | $22.05 | $28.7K Buy | Form 4 ↗ |
| Nov 18, 2025 | Tejraj S. Hada Director | GCBC Greene Bancorp, Inc. | Buy | 3,000 | $21.96 | $65.9K Buy | Form 4 ↗ |
| Nov 18, 2025 | John Antalek EVP and CLO | GCBC Greene Bancorp, Inc. | Buy | 1,500 | $22.00 | $33.0K Buy | Form 4 ↗ |
| Nov 14, 2025 | Tejraj S. Hada Director | GCBC Greene Bancorp, Inc. | Buy | 366 | $22.00 | $8,052 Buy | Form 4 ↗ |
| Nov 5, 2025 | Tejraj S. Hada Director | GCBC Greene Bancorp, Inc. | Buy | 1,500 | $22.52 | $33.8K Buy | Form 4 ↗ |
| Nov 4, 2025 | Tejraj S. Hada Director | GCBC Greene Bancorp, Inc. | Buy | 45 | $22.20 | $999 Buy | Form 4 ↗ |
| Nov 3, 2025 | Tejraj S. Hada Director | GCBC Greene Bancorp, Inc. | Buy | 235 | $21.80 | $5,123 Buy | Form 4 ↗ |
| Oct 29, 2025 | Donald E. Gibson President and CEO, Director | GCBC Greene Bancorp, Inc. | Buy | 500 | $21.75 | $10.9K Buy | Form 4 ↗ |
| Oct 29, 2025 | Donald E. Gibson President and CEO, Director | GCBC Greene Bancorp, Inc. | Buy | 500 | $22.00 | $11.0K Buy | Form 4 ↗ |
| Oct 29, 2025 | Christopher Cannucciari Director | GCBC Greene Bancorp, Inc. | Buy | 423 | $22.79 | $9,640 Buy | Form 4 ↗ |
| Oct 28, 2025 | Christopher Cannucciari Director | GCBC Greene Bancorp, Inc. | Buy | 706 | $22.91 | $16.2K Buy | Form 4 ↗ |
| Oct 24, 2025 | Jay P. Cahalan Director | GCBC Greene Bancorp, Inc. | Buy | 810 | $22.58 | $18.3K Buy | Form 4 ↗ |
| Oct 24, 2025 | Jay P. Cahalan Director | GCBC Greene Bancorp, Inc. | Buy | 402 | $22.72 | $9,133 Buy | Form 4 ↗ |
| Oct 24, 2025 | Jay P. Cahalan Director | GCBC Greene Bancorp, Inc. | Buy | 500 | $22.67 | $11.3K Buy | Form 4 ↗ |
| Oct 24, 2025 | Jay P. Cahalan Director | GCBC Greene Bancorp, Inc. | Buy | 10 | $22.62 | $226 Buy | Form 4 ↗ |
| Oct 24, 2025 | Jay P. Cahalan Director | GCBC Greene Bancorp, Inc. | Buy | 27 | $22.60 | $610 Buy | Form 4 ↗ |
| Oct 24, 2025 | Jay P. Cahalan Director | GCBC Greene Bancorp, Inc. | Buy | 1,700 | $22.82 | $38.8K Buy | Form 4 ↗ |
| Oct 24, 2025 | Jay P. Cahalan Director | GCBC Greene Bancorp, Inc. | Buy | 101 | $22.78 | $2,301 Buy | Form 4 ↗ |
| Oct 24, 2025 | Jay P. Cahalan Director | GCBC Greene Bancorp, Inc. | Buy | 600 | $22.75 | $13.7K Buy | Form 4 ↗ |
| Oct 24, 2025 | Jay P. Cahalan Director | GCBC Greene Bancorp, Inc. | Buy | 150 | $22.69 | $3,404 Buy | Form 4 ↗ |
| May 15, 2025 | Tejraj S. Hada Director | GCBC Greene Bancorp, Inc. | Buy | 388 | $22.95 | $8,905 Buy | Form 4 ↗ |
| May 14, 2025 | Tejraj S. Hada Director | GCBC Greene Bancorp, Inc. | Buy | 6,612 | $22.95 | $151.7K Buy | Form 4 ↗ |
| May 5, 2025 | Christopher Cannucciari Director | GCBC Greene Bancorp, Inc. | Buy | 10 | $22.50 | $225 Buy | Form 4/A ↗ |
| May 5, 2025 | Christopher Cannucciari Director | GCBC Greene Bancorp, Inc. | Buy | 38 | $22.50 | $855 Buy | Form 4/A ↗ |
| May 5, 2025 | Christopher Cannucciari Director | GCBC Greene Bancorp, Inc. | Buy | 38 | $22.50 | $855 Buy | Form 4 ↗ |
| May 2, 2025 | Christopher Cannucciari Director | GCBC Greene Bancorp, Inc. | Buy | 28 | $22.33 | $625 Buy | Form 4/A ↗ |
| May 2, 2025 | Christopher Cannucciari Director | GCBC Greene Bancorp, Inc. | Buy | 105 | $22.33 | $2,345 Buy | Form 4/A ↗ |
| May 2, 2025 | Christopher Cannucciari Director | GCBC Greene Bancorp, Inc. | Buy | 10 | $22.50 | $225 Buy | Form 4 ↗ |
| May 2, 2025 | Christopher Cannucciari Director | GCBC Greene Bancorp, Inc. | Buy | 28 | $22.33 | $625 Buy | Form 4 ↗ |
| May 2, 2025 | Christopher Cannucciari Director | GCBC Greene Bancorp, Inc. | Buy | 105 | $22.33 | $2,345 Buy | Form 4 ↗ |
| May 1, 2025 | Christopher Cannucciari Director | GCBC Greene Bancorp, Inc. | Buy | 290 | $22.20 | $6,438 Buy | Form 4/A ↗ |
| May 1, 2025 | Christopher Cannucciari Director | GCBC Greene Bancorp, Inc. | Buy | 290 | $22.20 | $6,438 Buy | Form 4 ↗ |
| Apr 25, 2025 | Nick Barzee SVP and CFO | GCBC Greene Bancorp, Inc. | Buy | 1,500 | $21.50 | $32.3K Buy | Form 4 ↗ |
| Mar 19, 2025 | Tejraj S. Hada Director | GCBC Greene Bancorp, Inc. | Buy | 2,000 | $23.25 | $46.5K Buy | Form 4 ↗ |
| Mar 19, 2025 | Tejraj S. Hada Director | GCBC Greene Bancorp, Inc. | Buy | 1,000 | $23.26 | $23.3K Buy | Form 4 ↗ |
| Mar 19, 2025 | Tejraj S. Hada Director | GCBC Greene Bancorp, Inc. | Buy | 4,000 | $23.50 | $94.0K Buy | Form 4 ↗ |
| Feb 28, 2025 | Jay P. Cahalan Director | GCBC Greene Bancorp, Inc. | Buy | 1,800 | $26.94 | $48.5K Buy | Form 4 ↗ |
| Feb 27, 2025 | Jay P. Cahalan Director | GCBC Greene Bancorp, Inc. | Buy | 1,944 | $26.45 | $51.4K Buy | Form 4 ↗ |
| Jan 31, 2025 | Nick Barzee SVP and CFO | GCBC Greene Bancorp, Inc. | Buy | 840 | $26.50 | $22.3K Buy | Form 4 ↗ |
| Nov 1, 2024 | Tejraj S. Hada Director | GCBC Greene Bancorp, Inc. | Buy | 2,000 | $28.00 | $56.0K Buy | Form 4 ↗ |
| Oct 25, 2024 | Nick Barzee SVP and CFO | GCBC Greene Bancorp, Inc. | Buy | 892 | $28.57 | $25.5K Buy | Form 4 ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:18 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances